Tumour heterogeneity poses a significant challenge to cancer biomarker research.

导出 OA

翻译打印收藏纠错

作者： Karolina,Cyll ^[1] ; Elin,Ersvær ^[1] ; Ljiljana,Vlatkovic ^[2] ; Manohar,Pradhan ^[1] ; Wanja,Kildal ^[1] ; Marte,Avranden Kjær ^[1] ; Andreas,Kleppe ^[3] ; Tarjei S,Hveem ^[3] ; Birgitte,Carlsen ^[4] ; Silje,Gill ^[5] ; Sven,Löffeler ^[5] ; Erik Skaaheim,Haug ^[5] ; Håkon,Wæhre ^[1] ; Prasanna,Sooriakumaran ^[6] ; Håvard E,Danielsen ^[7]

作者单位： Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway.;Centre for Cancer Biomedicine, University of Oslo, Oslo, NO-0424, Norway. ^[1] Department of Pathology, Oslo University Hospital, Oslo, NO-0424, Norway. ^[2] Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway.;Centre for Cancer Biomedicine, University of Oslo, Oslo, NO-0424, Norway.;Department of Informatics, University of Oslo, Oslo, NO-0316, Norway. ^[3] Department of Pathology, Vestfold Hospital Trust, NO-3103 Tønsberg, Norway. ^[4] Department of Urology, Vestfold Hospital Trust, Tønsberg, NO-3103, Norway. ^[5] Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK. ^[6] Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo NO-0424, Norway.;Centre for Cancer Biomedicine, University of Oslo, Oslo, NO-0424, Norway.;Department of Informatics, University of Oslo, Oslo, NO-0316, Norway.;Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford OX3 9DU, UK. ^[7]